MDxHealth Dividends and Buybacks
Dividend criteria checks 0/6
MDxHealth does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-5.9%
Buyback Yield
| Total Shareholder Yield | -5.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
MDXH: Upcoming Study Readouts Will Refocus Pure-Play Prostate Cancer Potential
Analysts have adjusted their average MDxHealth price target from about $5.00 to roughly $3.00 following updated models after recent financings and product changes. They continue to describe the company as a focused prostate cancer diagnostics player with important study readouts expected in the future.
MDXH: Upcoming Clinical Readouts Will Trigger Reassessment Of Depressed Share Price
Analysts have reduced their price targets for MDxHealth to a range centered around $2, reflecting updated models after the Resolve wind-down, the transfer of liabilities to Novitas, and recent equity offerings, while still citing the company's positioning in prostate cancer diagnostics as a key support for their long term thesis. Analyst Commentary Recent research updates on MDxHealth focus on how the Resolve wind down, the transfer of related liabilities, and new equity issuance feed into valuation, while also highlighting the company’s role in prostate cancer diagnostics.MDXH: Upcoming Clinical Readouts Will Drive Reassessment Of Depressed Share Price
Analysts have reduced their price target on MDxHealth stock to $3 from $5, highlighting the impact of the increased share count while still pointing to upcoming clinical readouts and recent study publications as key supports for the revised outlook. What's in the News for MDxHealth MDxHealth issued earnings guidance for 2026 with expected revenue in a range of US$110 million to US$115 million.
MDXH: Future Upside Will Hinge On Resolving The 10.4m Medicare Recoupment
Analysts have reset expectations for MDxHealth, cutting price targets from as high as $9 to a range of $1.50 to $5, as they factor in weaker Q1 results, the exit from the Resolve UTI business, and reimbursement uncertainty that affects revenue growth, profit margin assumptions, and the future P/E multiple. Analyst Commentary Recent Street commentary around MDxHealth reflects a more cautious tone, with several bearish analysts reassessing the risk profile after weaker Q1 results, the planned exit from the Resolve UTI business, and questions around Medicare reimbursement.MDXH: Resolve Exit And Medicare Review Will Reset Prostate Cancer Focus
Analysts have sharply reduced their price targets on MDxHealth, with cuts such as $7 to $1.50, $9 to $5, and $7 to $4, reflecting weaker Q1 revenue, lowered guidance, and the exit of the Resolve UTI business following reimbursement and recoupment disputes. Analyst Commentary Recent research on MDxHealth highlights a mix of caution and optimism, with analysts reacting to weaker Q1 revenue, revised guidance, and the exit of the Resolve UTI business.MDXH: Resolve Exit And Medicare Review Will Refocus On Prostate Cancer
Analysts have cut their fair value estimate for MDxHealth from $9.00 to $5.00, citing reduced revenue growth assumptions, a higher discount rate, and a lower future P/E multiple after the Q1 miss, the Resolve exit, and reimbursement uncertainties. Analyst Commentary Recent Street research on MDxHealth reflects a reset in expectations after the Q1 shortfall, the Resolve exit, and reimbursement questions, but also highlights areas where analysts still see potential for execution and valuation recovery.MDXH: Future Upside Will Depend On Resolving The 10.4m Medicare Dispute
Analysts have reduced their fair value estimate for MDxHealth from $4.20 to $1.00 following weak Q1 results, lower revenue guidance, the discontinuation of the Resolve UTI test, and uncertainty surrounding a $10.4m Medicare recoupment notice and the closure of the related Texas lab. Analyst Commentary on MDxHealth Recent Street research on MDxHealth highlights a clear shift toward caution, with several bearish analysts cutting price targets and reassessing the risk profile after the weak Q1 update, reduced revenue guidance, the Medicare recoupment notice of $10.4m, and the decision to close the Texas lab tied to the Resolve UTI test.MDxHealth SA (NASDAQ:MDXH) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
MDxHealth SA ( NASDAQ:MDXH ) shareholders won't be pleased to see that the share price has had a very rough month...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if MDXH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDXH's dividend payments have been increasing.
Dividend Yield vs Market
| MDxHealth Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (MDXH) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.1% |
| Analyst forecast (MDXH) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate MDXH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDXH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate MDXH's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDXH has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 08:30 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MDxHealth SA is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ruzic-Gauthier | Berenberg |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |